- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810496
Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia (MUTA-GR)
January 19, 2026 updated by: CHU de Reims
Prevalence of Mutations of Glucocorticoid Receptors in Bilateral Adrenal Hyperplasia
As the investigators observed a case of glucocorticoid mutation revealed by incidentally discovered bilateral adrenal nodular hyperplasia, it was postulated that this molecular anormality could be more frequent than previously described.
To validate this hypothesis, it was decided to study 150 multicenter consecutive patients, presenting with incidentally discovered bilateral adrenal masses without clinical signs of Cushing's disease.
In all these patients GR gene will be studied, mutations will be detected and described, functional disturbance will be tested.
Usual polymorphisms will be described.
Correlation between clinical signs, hormonal and morphological abnormalities and presence or absence of GR mutations will be searched.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Reims, France, 51092
- CHU Reims
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- patients more than 18 years of age
- patients with bilateral adrenal masses
Exclusion Criteria:
- Refusing to participate in the study
- Protected by law
- Have obvious signs of Cushing's syndrome
- No progressive neoplastic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
frequency of mutations
Time Frame: DAY 0
|
DAY 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Vitellius G, Delemer B, Caron P, Chabre O, Bouligand J, Pussard E, Trabado S, Lombes M. Impaired 11beta-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5205-5216. doi: 10.1210/jc.2019-00800.
- Vitellius G, Trabado S, Hoeffel C, Bouligand J, Bennet A, Castinetti F, Decoudier B, Guiochon-Mantel A, Lombes M, Delemer B; investigators of the MUTA-GR Study. Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: results of the French MUTA-GR Study. Eur J Endocrinol. 2018 Apr;178(4):411-423. doi: 10.1530/EJE-17-1071. Epub 2018 Feb 14.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2012
Primary Completion (Actual)
October 2, 2016
Study Completion (Actual)
December 31, 2016
Study Registration Dates
First Submitted
June 16, 2016
First Submitted That Met QC Criteria
June 20, 2016
First Posted (Estimated)
June 23, 2016
Study Record Updates
Last Update Posted (Actual)
January 21, 2026
Last Update Submitted That Met QC Criteria
January 19, 2026
Last Verified
August 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Endocrine System Diseases
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Adrenal Gland Diseases
- Steroid Metabolism, Inborn Errors
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hyperplasia
- Adrenal Hyperplasia, Congenital
- Adrenogenital Syndrome
Other Study ID Numbers
- PN11010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on General Glucocorticoid Resistance
-
National Institute of Diabetes and Digestive and...CompletedACTH | Glucocorticoid | Cortisol Resistance | Negative Feedback | MineralcorticoidUnited States
-
Rambam Health Care CampusUnknown
-
Max Healthcare Insititute LimitedCompletedGlucocorticoid Induced HyperglycemiaIndia
-
University Hospital, Basel, SwitzerlandCompletedPatients With Glucocorticoid TreatmentSwitzerland
-
AmgenCompletedSteroid-induced Osteopor, Glucocorticoid-induced OsteporDenmark, Netherlands, Belgium, United States, Czechia, Poland, Russian Federation, Hungary, Korea, Republic of, Spain, Germany, France, Canada, Argentina, Colombia, Mexico
-
Amsterdam UMC, location VUmcNational Research Council, Institute of Biomedical EngineeringCompletedGlucocorticoid-induced Glucometabolic Abnormalities | Glucocorticoid-induced Beta-cell DysfunctionNetherlands
-
Eleonora SeeligCompletedGlucocorticoid EffectSwitzerland
-
Eleonora SeeligCompletedGlucocorticoid EffectSwitzerland
-
Arkansas Children's Hospital Research InstituteWithdrawnInsulin Resistance | Body Composition, Beneficial | Liver Steatosis | Whole Body Protein Metabolism
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); AllerGen NCE Inc.RecruitingExposure to Pollution | Glucocorticoid ResistanceCanada
Clinical Trials on blood collection for mutation characterization
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingVon Willebrand Disease (VWD) | Acquired Von Willebrand DiseaseItaly
-
Medical University of WarsawMedical Research Agency, PolandRecruitingColorectal Cancer Metastatic | HCC - Hepatocellular CarcinomaPoland
-
Centre Hospitalier Universitaire de la RéunionRecruitingBreast Cancer | BRCA2 Mutation | Genetic DiseaseFrance
-
Francisco Algaba ChuecaHospital Universitari Joan XXIII de Tarragona.Recruiting
-
Sir Run Run Shaw HospitalCompletedCatheter ComplicationsChina
-
Hans SmitRijnstate Hospital; Prof. Dr. Jaap Swieringa stichting; Mr. Willem Bakhuys RoozeboomstichtingUnknown
-
Fondazione del Piemonte per l'OncologiaUnknownGastrointestinal Stromal Tumor (GIST)Italy
-
University of UtahDepartment of Health and Human ServicesCompletedLow Birth Weight | Immunodeficiency | Small for Gestational AgeUnited States
-
Gritstone bio, Inc.CompletedMetastatic Colorectal Cancer | Stage II/III Colon CancerUnited States
-
Université Catholique de LouvainRecruitingChronic Obstructive Pulmonary Disease | Sarcoidosis | Immune Dysregulation | Lung Cancer (Diagnosis) | Immunotherapy ResistanceBelgium